Facebook
Linkedin
Twitter
Industries
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Search
Friday, November 22, 2024
Facebook
Linkedin
Twitter
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
ReadMagazine
Industries
All
Aerospace
Agritech
Automotive
BFSI
Biotechnology
Chemicals
Defence Technology
Energy, Power and Sustainability
Food & Beverage
Healthcare
Information Technology
MarTech
Internet Of Things (IOT)
Logistics and Supply Chain
Materials
Medical Devices
Retail
Semiconductor & Electronics
Smart Lighting
Read Magazine’s Weekly News Roundup With BAE Systems, Messer, Irdeto, OneStream,…
Capgemini Named Leader in IDC Worldwide Sustainability
Element Energy Boosts Second-Life Battery Deployment
Monta and Emobi Partner for Reliable EV Charging Solutions
Latest News
Interviews
Insights
Guest Post
Staff Writer
Featured Article
Resource Center
Resources
Press Releases
Home
Tags
Robert O. Dillman
Robert O. Dillman
Biotechnology
AIVITA Biomedical Announces Publication of Phase 1 and Phase 2 Trial Results of its COVID-19 Vaccine Candidate
PR Newswire
-
September 1, 2022
AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and...
0
Fans
Like
3,912
Followers
Follow
0
Subscribers
Subscribe
Hot Topics
Read Magazine’s Weekly News Roundup With BAE Systems, Messer, Irdeto, OneStream, Pfizer, And More!
Capgemini Named Leader in IDC Worldwide Sustainability
Element Energy Boosts Second-Life Battery Deployment
Load more
